Perampanel

Perampanel
Clinical data
Trade names	Fycompa
Other names	E2007
AHFS/Drugs.com	Monograph
MedlinePlus	a614006
License data	US DailyMed: Perampanel;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth
Drug class	Anticonvulsant
ATC code	N03AX22 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class B1 (Psychoactive drugs); CA: ℞-only; UK: POM (Prescription only); US: Schedule III; EU: Rx-only;
Pharmacokinetic data
Bioavailability	116%
Protein binding	95–96%
Metabolism	Liver, mostly via CYP3A4 and/or CYP3A5
Elimination half-life	105 hours, 295 hours (moderate hepatic impairment)
Excretion	70% faeces, 30% urine
Identifiers
	IUPAC name 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'(1H)-one;
CAS Number	380917-97-5 ; as hydrate: 1571982-04-1;
PubChem CID	9924495; as hydrate: 70679123;
IUPHAR/BPS	7050;
DrugBank	DB08883 ; as hydrate: DBSALT001824;
ChemSpider	8100130 ; as hydrate: 28533413;
UNII	H821664NPK; as hydrate: 8LIX22217M;
KEGG	D08964 ; as hydrate: D10780;
ChEBI	CHEBI:71013 ; as hydrate: CHEBI:71015;
ChEMBL	ChEMBL1214124 ;
PDB ligand	6ZP (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID80191501 ;
ECHA InfoCard	100.219.846
Chemical and physical data
Formula	C23H15N3O
Molar mass	349.393 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N#Cc2ccccc2-c1cc(-c4ncccc4)cn(c1=O)-c3ccccc3;
	InChI InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22) 16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H ; Key:PRMWGUBFXWROHD-UHFFFAOYSA-N ; ; as hydrate: InChI=1S/4C23H15N3O.3H2O/c424-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19;;;/h41-14,16H;3*1H2; Key:PDWMJDKMSASBNE-UHFFFAOYSA-N;
	(what is this?) (verify)

Perampanel, sold under the brand name Fycompa, is an anti-epileptic medication developed by Eisai that is used in addition to other medications to treat partial seizures and generalized tonic–clonic seizures. Perampanel is a non-competitive AMPA glutamate receptor antagonist. It is taken by mouth.

Perampanel was approved in 2012, and as of 2016, its optimal role in the treatment of epilepsy relative to other drugs is not clear. It is the first anti-epileptic drug in the class of selective non-competitive antagonist of AMPA receptors.

The US prescribing information has a boxed warning that perampanel may cause serious psychiatric and behavioral changes; it may cause homicidal or suicidal thoughts. Other side effects have included dizziness, somnolence, vertigo, aggression, anger, loss of coordination, blurred vision, irritability, and slurred speech. Perampanel reduced the effectiveness of levonorgestrel oral contraceptives by about 40%. Women who may get pregnant should not take it as studies in animals show it may harm a fetus. Perampanel is liable to be abused; very high doses produced euphoria responses similar to ketamine. It is designated as a Schedule III controlled substance by the US Drug Enforcement Administration. Perampanel is authorized as a generic medication.